ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q2 EPS of ($0.46), in-line with the analyst estimate of ($0.46). Revenue for the quarter came in at $15.72 million versus the consensus estimate of $13.77 million.

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.